progressive supranuclear palsy Syndicate content

Jul 31, 2019

INCHEON, South Korea, July 31, 2019 /PRNewswire/ -- Samsung BioLogics (SBL) and UCB have agreed to an additional drug substance manufacturing deal under which SBL will also produce UCB's anti-tau candidate to treat progressive supranuclear palsy, pending regulatory approvals. UCB's anti-tau candidate is currently...